TARGET FIRST is a prospective, international, multicentre, open-label, randomized (1:1) post-market study to evaluate a modified Anti-Platelet Therapy associated with low-dose rapamycin DES Firehawk in Acute Myocardial Infarction Patients treated with complete revascularization strategy. The modified antiplatelet therapy consists of a reduced duration of DAPT (1 month duration) followed by P2Y12 inhibitor monotherapy up to 12 months.
Sponsor
Primary endpoints
Net Adverse Clinical and Cerebral Events (NACCE) defined as a composite of all cause death, non-fatal myocardial infarction, definite/probable stent thrombosis, stroke, or Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding at 11 months post randomization (12 months post index procedure).
CERC Services
- Site qualification
- Regulatory submissions
- Project management
- Monitoring activities
- SAE Reporting
- CEC activities
Countries
6 (Austria, France, Italy, The Netherlands, Portugal, Spain)
Number of investigational sites
40 sites
Number of patients
2246
